arrow
A

Ajay Vora

University of Birmingham
H指数:66
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of treosulfan exposure on clinical outcome after allogeneic stem cell transplantation in children: A substudy of 2 phase 2 trials

treosulfan暴露对儿童异基因干细胞移植后临床结局的影响: 2项2期试验的子研究

2024-11-190
PRE
Blinatumomab with De-Escalated Chemotherapy for Infant KMT2A-Rearranged B-Cell Acute Lymphoblastic Leukemia

Blinatumomab联合降阶梯化疗治疗婴儿KMT2A重排B细胞急性淋巴细胞白血病

BLOOD
IF23.1
2024-11-052
PRE
Whole genome sequencing provides practice-changing benefits when performed on consecutive, unselected children with suspected cancer
2024-09-050
PRE
Benefits for children with suspected cancer from routine whole-genome sequencing
2024-07-025
OAAI
Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy
2024-04-155
OAAI
Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme
2024-04-150
OAAI
Whole genome sequencing provides comprehensive genetic testing in childhood B-cell acute lymphoblastic leukaemia
LEUKEMIA
IF13.4
2023-01-1932
OAAI
Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial

在UKALL2003临床试验中缺乏遗传生物标志物的儿童急性淋巴细胞白血病的综合基因组分析

LEUKEMIA
IF13.4
2022-12-2215
OAAI
Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol
2022-01-019
OA
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial

儿童和年轻成人复发或难治性b细胞急性淋巴细胞白血病患者中CD19和CD22双重靶向的CAR T细胞: 1期试验

2021-10-12163
OAAI